Medinger Michael, Mross Klaus
Department of Medical Oncology, Tumor Biology Center at the Albert-Ludwigs-University, Breisacherstrasse 117, D-79106 Freiburg, Germany.
J Angiogenes Res. 2010 Jun 22;2:10. doi: 10.1186/2040-2384-2-10.
New blood vessel formation (angiogenesis) is not only essential for the growth of solid tumors but there is also emerging evidence that progression of hematological malignancies like multiple myeloma, acute leukemias, and myeloproliferative neoplasms, also depends on new blood vessel formation. Anti-angiogenic strategies have become an important therapeutic modality for solid tumors. Several anti-angiogenic agents targeting angiogenesis-related pathways like monoclonal antibodies, receptor tyrosine kinase inhibitors, immunomodulatory drugs, and proteasome inhibitors have been entered clinical trials or have been already approved for the treatment of hematological malignancies as well and in some instances these pathways have emerged as promising therapeutic targets. This review summarizes recent advances in the basic understanding of the role of angiogenesis in hematological malignancies and clinical trials with novel therapeutic approaches targeting angiogenesis.
新血管形成（血管生成）不仅对实体瘤的生长至关重要，而且越来越多的证据表明，血液系统恶性肿瘤如多发性骨髓瘤、急性白血病和骨髓增殖性肿瘤的进展也依赖于新血管形成。抗血管生成策略已成为实体瘤的一种重要治疗方式。几种靶向血管生成相关途径的抗血管生成药物，如单克隆抗体、受体酪氨酸激酶抑制剂、免疫调节药物和蛋白酶体抑制剂，已进入临床试验，或已被批准用于治疗血液系统恶性肿瘤，在某些情况下，这些途径已成为有前景的治疗靶点。本文综述了血管生成在血液系统恶性肿瘤中的作用的基础研究最新进展，以及针对血管生成的新型治疗方法的临床试验。
Zotero 插件